CN103038256A - 用抗cd3免疫分子疗法治疗肝炎的方法及组合物 - Google Patents

用抗cd3免疫分子疗法治疗肝炎的方法及组合物 Download PDF

Info

Publication number
CN103038256A
CN103038256A CN2011800284648A CN201180028464A CN103038256A CN 103038256 A CN103038256 A CN 103038256A CN 2011800284648 A CN2011800284648 A CN 2011800284648A CN 201180028464 A CN201180028464 A CN 201180028464A CN 103038256 A CN103038256 A CN 103038256A
Authority
CN
China
Prior art keywords
hepatitis
composition
oral
antibody
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800284648A
Other languages
English (en)
Chinese (zh)
Inventor
亚龙·伊兰
罗纳德·埃利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
NASVAX Ltd
Original Assignee
Hadasit Medical Research Services and Development Co
NASVAX Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, NASVAX Ltd filed Critical Hadasit Medical Research Services and Development Co
Publication of CN103038256A publication Critical patent/CN103038256A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2011800284648A 2010-04-29 2011-04-29 用抗cd3免疫分子疗法治疗肝炎的方法及组合物 Pending CN103038256A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32955410P 2010-04-29 2010-04-29
US61/329,554 2010-04-29
PCT/IB2011/051900 WO2011135544A2 (en) 2010-04-29 2011-04-29 Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy

Publications (1)

Publication Number Publication Date
CN103038256A true CN103038256A (zh) 2013-04-10

Family

ID=44629291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800284648A Pending CN103038256A (zh) 2010-04-29 2011-04-29 用抗cd3免疫分子疗法治疗肝炎的方法及组合物

Country Status (9)

Country Link
US (1) US20130078238A1 (https=)
EP (1) EP2563815A2 (https=)
JP (2) JP2013525420A (https=)
KR (1) KR20130066626A (https=)
CN (1) CN103038256A (https=)
AU (1) AU2011246893A1 (https=)
BR (1) BR112012027531A2 (https=)
CA (1) CA2804976A1 (https=)
WO (1) WO2011135544A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090656A2 (en) * 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4654210A (en) 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (en) 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
US8940479B2 (en) * 2008-01-14 2015-01-27 Cornell University Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090656A2 (en) * 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ORENBUCH-HARROCH E.等: "ORAL ADMINISTRATION OF ANTI CD3-MONOCLONAL ANTIBODIES PROMOTES CD4+CD25+ LAP+ AND NKT LAP+ REGULATORY T LYMPHOCYTES AND AMELIORATES HEPATITIS BY INHIBITING CASPASE 3-MEDIATED APOPTOSIS", 《JOURNAL OF HEPATOLOGY》, 30 April 2009 (2009-04-30) *
YOUNOSSI Z.: ""current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis"", 《ALIMENTARY PHARMACOLOGY & THERAPEUTICS》, vol. 28, no. 1, 31 July 2008 (2008-07-31), pages 2 - 12, XP002661670, DOI: doi:10.1111/J.1365-2036.2008.03710.X *
周忠海等: "乙肝患者自身CD3AK细胞抗病毒近期疗效观察", 《胃肠病学和肝病学杂志》, no. 05, 20 October 2003 (2003-10-20) *
黄俭等: "慢性乙型肝炎患者外周血细胞因子诱导的杀伤细胞的动态观察", 《细胞与分子免疫学杂志》, no. 06, 30 December 2003 (2003-12-30) *

Also Published As

Publication number Publication date
WO2011135544A3 (en) 2012-01-05
US20130078238A1 (en) 2013-03-28
JP2013525420A (ja) 2013-06-20
CA2804976A1 (en) 2011-11-03
WO2011135544A2 (en) 2011-11-03
EP2563815A2 (en) 2013-03-06
KR20130066626A (ko) 2013-06-20
AU2011246893A1 (en) 2012-11-08
JP2016172759A (ja) 2016-09-29
BR112012027531A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
CN103038256A (zh) 用抗cd3免疫分子疗法治疗肝炎的方法及组合物
JP7688360B2 (ja) 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
TWI814575B (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法
JP5027512B2 (ja) 免疫調節法
US20190040126A1 (en) Methods for treating active eosinophilic esophagitis
TWI634900B (zh) 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
CN115768516A (zh) 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
US9981037B2 (en) Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
JP7811933B2 (ja) 活動性好酸球性食道炎を治療する方法
US20230227555A1 (en) Cd-3 antibodies for the treatment of coronavirus
US20240350626A1 (en) Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
US20240336688A1 (en) Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
US20240425591A1 (en) Methods of suppressing microglial activation
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
Whangbo et al. Chronic Graft-Versus-Host Disease
CN121693519A (zh) Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
AU2021239983A1 (en) Injectable formulation of poly(lactic-co-glycolic (PLGA)) microspheres encapsulating siltuximab
Bagel Evaluating the interleukin antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130410